Warsaw-Based Holi Raises €3M To Expand Its Digital Obesity Treatment Platform

The round was led by 4growth VC, with participation from YZR Capital, Heartfelt Capital, and several business angels.

“Obesity treatment requires continuity and the integration of multiple medical competencies,” says Paweł Seweryn, Founder & CEO of Holi. “Our goal is to deliver a comprehensive solution that leads to real, long-term change in metabolic health. The funding will enable us to scale our model internationally – starting with the Southern and Eastern Europe markets, which are highly receptive to private healthcare and telemedicine – while further developing our technology stack.”

EU-Startups had earlier reported Holi’s €680k pre-Seed round in 2023, highlighting its early momentum. The latest funding marks a natural progression from proof-of-concept to regional expansion, in line with 2025’s growing focus on hybrid, data-driven approaches to metabolic health management.

Read Also - Germany’s The Icon League Scores €15M Series A To Expand Five-A-Side Football Format And €500K Prize Pool

“The next generation of obesity treatment will be hybrid – data and AI for precision, experts for impact. Our platform continuously analyses patient data to adjust therapy in real time, while doctors and specialists step in exactly when human intervention matters most. That’s how we deliver better outcomes with smarter use of medication,” explains Jan Kundziołka, Co-founder of Holi, responsible for product and technology.

Founded in 2023, Holi is a Polish digital obesity clinic that blends multidisciplinary medical care covering doctors, psychodietitians, psychologists, and physiotherapists with technology to support lifestyle changes and pharmacotherapy.

The platform also provides access to GLP-1-based treatments like Ozempic and Wegovy, enabling personalised care through its mobile app and specialist platform. Operating on a subscription model, Holi focuses on treating the root causes of obesity, not just the symptoms.

The new funding will support the expansion of its medical infrastructure and enhance its technology with diagnostic integration, GLP-1 tracking, care automation, and new engagement tools to sustain patient motivation.

Holi reports that patients achieve an average 17% weight reduction after 12 months—1.5x higher than medication alone while also reducing drug costs by up to 50% through data-driven dose optimisation and behavioural coaching.

“Obesity remains one of the most underserved health needs globally. Holi has built a truly efficient care model – virtual, scalable and designed with a genuine value-for-money mindset. It delivers clinically proven outcomes at a price point that makes sense for both patients and the business. This combination of medical impact and smart product ​design is exactly what convinced us to invest,” says Krzysztof Bachta, Managing Partner at 4growth VC.

Europe’s obesity treatment market is valued between €40–50 billion, with private healthcare spending climbing quickly as GLP-1 drugs like Ozempic, Wegovy, and Mounjaro see increasing adoption among patients.

“Since our initial investment, Holi has shown remarkable progress – both in clinical outcomes and operational execution. The company is scaling fast while maintaining strong medical standards, which is rare in this market. That’s exactly why we decided to significantly increase our backing in this round,” says Markus Feuerecker, Co-founder and Managing Partner at YZR Capital.

About Holi

Holi is a fully digital metabolic health clinic redefining how obesity and related conditions are treated. By combining advanced diagnostics with innovative therapies, Holi offers personalized, data-driven care to help patients achieve lasting weight loss and improved overall health.